As the regulatory burden in medtech grows, a structured approach to using generative AI can provide dramatic gains in efficiency, accuracy, and other key metrics.
Education
- PhD in Structural Biology, University of Oxford
- MBA, London Business School
Chris Meier is a core member of Boston Consulting Group's Health Care practice focusing on pharmaceutical R&D, and medical and commercial topics. He is also a core member of BCG X, the firm's data science unit. Chris serves as the global lead for medical and innovation within the Health Care practice, as well as the global lead for AI, data, and analytics in biopharma.
Before joining BCG, Chris was a principal scientist in the pharmaceutical industry working in drug discovery research. In his industrial work he contributed to the discovery of several drug molecules in autoimmune diseases and oncology.
